Cholestasis is a hereditary or acquired impairment of bile formation and flow on either a hepatocellular or a cholangiocellular level, resulting in interruption of the enterohepatic circulation of bile acids. A general goal in treating cholestasis, therefore, is to reduce hepatic and systemic bile acid accumulation and to decrease bile acid pool size. Farnesoid X receptor (FXR) represents the central integrator of bile acid homeostasis and, once activated, results in the reduction of cellular bile acid levels. Synthetic and semi-synthetic FXR agonists, with higher affinity and potency to activate FXR, have been successfully tested in animal models of cholestasis. This clinical phase II trial showed that the impact of the semi-synthetic steroidal FXR ligand obeticholic acid (OCA) on cholesterol metabolism was pronounced in obese patients with non-alcoholic fatty liver disease (NAFLD) as the disease target, where not only high-density lipoprotein cholesterol decreased but also low-density lipoprotein cholesterol increased. This Recommendation is of an article referenced in an F1000 Faculty Review also written by Martin Wagner and Michael Trauner.